GlassScriptPhysician profile
Alonzo J Flores
NPI 1518013978
$2,941.86
in general payments reported to CMS, 2019-2025
23 companies · $13.53 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $220 · 2021: $724 · 2022: $596 · 2023: $601 · 2024: $14.41 · 2025: $13.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $581.30 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $258.28 | 2019-2020 | |
| Lilly USA, LLC | $254.38 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $253.68 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Novo Nordisk INC | $225.47 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $199.27 | 2019-2023 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $183.80 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.48 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.87 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $154.35 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.93 | 2019 | |
| Biogen, INC. | $51.33 | 2022-2023 | Spinraza |
| Abbott Laboratories | $50.15 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.71 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.48 | 2019 | |
| Inari Medical, INC. | $34.60 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiovascular Systems INC. | $32.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.22 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $22.86 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $21.44 | 2021 | |
| Tactile Systems Technology INC | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alonzo Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.